Skip to main content
Top
Published in: Rheumatology International 7/2016

01-07-2016 | Observational Research

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome

Authors: Isha Saini, Mani Kalaivani, Sushil Kumar Kabra

Published in: Rheumatology International | Issue 7/2016

Login to get access

Abstract

The aim was to retrospectively estimate the prevalence of calcinosis in patients with juvenile dermatomyositis (JDM) and to identify risk factors associated with development of calcinosis in these patients. Retrospective chart review of 39 children diagnosed with JDM between 2004 and 2015 in a tertiary care hospital was done. Patients were divided into two groups, depending on the presence or absence of calcinosis, and the two groups were compared with respect to demographic, clinical, laboratory and therapeutic characteristics. Calcinosis developed in nine (23.1 %) patients. Delay in diagnosis and initiation of treatment, prolonged duration of disease, the presence of joint contractures and cardiac involvement were significantly associated with increased frequency of calcinosis. Six out of nine (66.7 %) patients with calcinosis received alendronate therapy, out of which four showed partial reduction in calcinosis. In one case, surgical removal of tumorous clumps was done. Calcinosis remains a common complication of JDM. We found an association between calcinosis and delay in diagnosis and initiation of treatment, prolonged duration of disease and cardiac involvement. Our study suggests that alendronate may be beneficial in management of calcinosis of JDM.
Literature
1.
go back to reference Rider LG, Lindsley CB, Cassidy JT (2005) Juvenile dermatomyositis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 375–413 Rider LG, Lindsley CB, Cassidy JT (2005) Juvenile dermatomyositis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 375–413
2.
go back to reference Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441–446CrossRefPubMed Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441–446CrossRefPubMed
3.
go back to reference Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S (2012) Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 41:50–58CrossRefPubMed Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S (2012) Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 41:50–58CrossRefPubMed
4.
go back to reference Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48:1541–1547CrossRef Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48:1541–1547CrossRef
5.
go back to reference Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldmen BM et al (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60:3425–3435CrossRefPubMedPubMedCentral Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldmen BM et al (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60:3425–3435CrossRefPubMedPubMedCentral
6.
go back to reference Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62:63–72CrossRef Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62:63–72CrossRef
7.
go back to reference Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM et al (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27:1031–1038PubMed Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM et al (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27:1031–1038PubMed
8.
go back to reference Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed
9.
go back to reference Efthimiou P, Kukar M, Kagen LJ (2010) Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol 37:194CrossRefPubMed Efthimiou P, Kukar M, Kagen LJ (2010) Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol 37:194CrossRefPubMed
10.
go back to reference Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888CrossRefPubMed Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888CrossRefPubMed
11.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed
12.
go back to reference Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766CrossRefPubMed Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766CrossRefPubMed
13.
go back to reference Pachman LM, Boskey AL (2006) Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep 8:236–243CrossRefPubMed Pachman LM, Boskey AL (2006) Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep 8:236–243CrossRefPubMed
14.
go back to reference Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511CrossRefPubMed Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511CrossRefPubMed
15.
go back to reference Pachman LM, Maryjowski MC (1984) Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 10:95–115PubMed Pachman LM, Maryjowski MC (1984) Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 10:95–115PubMed
16.
go back to reference Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28:833–857CrossRefPubMed Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28:833–857CrossRefPubMed
17.
go back to reference Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed
18.
go back to reference Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterized by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol 12:2CrossRef Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterized by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol 12:2CrossRef
19.
go back to reference Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729CrossRefPubMedPubMedCentral Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729CrossRefPubMedPubMedCentral
20.
go back to reference Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arthritis Rheum 37:R10ACrossRef Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arthritis Rheum 37:R10ACrossRef
21.
go back to reference Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74CrossRef Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74CrossRef
22.
go back to reference Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668–1678CrossRefPubMed Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668–1678CrossRefPubMed
23.
go back to reference Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511–520CrossRefPubMed Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511–520CrossRefPubMed
24.
go back to reference Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72CrossRefPubMed Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72CrossRefPubMed
25.
go back to reference Marco Puche A, Calvo PI, Lopez MB (2010) Effectiveness of treatment with intravenous pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed Marco Puche A, Calvo PI, Lopez MB (2010) Effectiveness of treatment with intravenous pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed
26.
go back to reference Ambler GR, Chaitow J, Rogers M, McDonald D, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed Ambler GR, Chaitow J, Rogers M, McDonald D, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed
Metadata
Title
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome
Authors
Isha Saini
Mani Kalaivani
Sushil Kumar Kabra
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3467-6

Other articles of this Issue 7/2016

Rheumatology International 7/2016 Go to the issue